KPLKwality Pharmaceuticals Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Kwality Pharmaceuticals Limited, together with its subsidiary, manufactures finished pharmaceutical formulations in India and internationally. The company offers its products in various dosage forms, including liquid orals, powder for oral suspension, dry syrups, tablets, capsules, sterile powder for injections, small volume parentals (liquid and lyophilized), pre filled syringes, ointments and creams, ophthalmic preparations, eye/ear drops, sanitizers, suppositories, injectable vials and ampoules, lyophilized products, syrups, daunorubicin, and various other categories such as general, beta-lactam, cephalosporins, cytotoxic (oncology), and biological. It also provides intermediates, chemicals, extracts, alkaloids, toilet requisites, beverages, and other medical preparations. Kwality Pharmaceuticals Limited was incorporated in 1983 and is based in Amritsar, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on KPL — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Revenue growth: 45.6% YoY
- • Profit growth: 114.9% YoY
- • ROE: 20.3%
- • Supertrend: bullish
- • 3-month return: +27.8%
- • 3-month vs NIFTY: +32.1% relative
Bull case
- • Revenue growth: 45.6% YoY
- • Profit growth: 114.9% YoY
- • ROE: 20.3%
- • Supertrend: bullish
Bear case
- • Dividend yield: 0.00%
- • MACD: bearish
- • Price vs EMA21: below
- • 1-month return: -7.1%
Key risks
- • Dividend yield: 0.00%
- • MACD: bearish
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹183.40). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.